Willingness to pay: A feasible method for assessing treatment benefits in epilepsy?

Seizure

Volumn 8, Issue 1, 1999, Pages 14-19

  Stavem, Knut ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Contingent valuation; Epilepsy; Evaluation; Health economics; Willingness to pay

Indexed keywords

ADULT; AGED; ARTICLE; EPILEPSY; FEMALE; HEALTH ECONOMICS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 0032975302     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.1998.0242     Document Type: Article

References (38)

1. Silfvenius, H. Economic costs of epilepsy-treatment benefits. Acta Neurologica Scandinavica 1988; 117 (Suppl.): 136-143.
2. Gessner, U., Sagmeister, M. and Horisberger, B. The cost of epilepsy in Switzerland. International Journal of Health Sciences 1993; 4: 121-128.
3. Cockerell, O. C., Hart, Y. M., Sander, J. W. and Shorvon, S. D. The cost of epilepsy in the United Kingdom: An estimation based on the results of two population-based studies. Epilepsy Research 1994; 18: 249-260.
4. Beran, R. G. and Banks, G. K. Indirect costs of epilepsy in Australia. In: Cost of Epilepsy. (Eds R. G. Beran and C. P. Packlatko). Wehr/Baden, Ciba-Geigy Verlag, 1995: pp. 49-54.
5. Cockerell, O. C., Hart, Y. M., Sander, J. W. A. S. and Shorvon, S. D. The cost of epilepsy in the United Kingdom. In: Cost of Epilepsy. (Eds R. G. Beran and C. P. Pachlatko). Wehr/Baden, Ciba-Geigy Verlag, 1995: pp. 27-37.
6. Gessner, U., Sagmeister, M. and Horisberger, B. The economic impact of epilepsy in Switzerland. In: Cost of Epilepsy. (Eds R. G. Beran andC. P. Pachlatko). Wehr/Baden, Ciba-Geigy Verlag, 1995: pp. 67-74.
7. Jacoby, A., Buck, D., Baker, G., McNamee, P., Graham-Jones, S. and Chadwick, D. Uptake and costs of care for epilepsy: Findings from a U.K. regional study. Epilepsia 1998; 39: 776-786.
8. Shorvon, S. Models of economic appraisals in epilepsy. In: Economic Evaluation of Epilepsy Management. (Eds C. Pachlatko and R. G. Beran). London, John Libbey & Co., 1996: pp. 19-26.
9. Pachlatko, C. Economic aspects of epilepsy: The state of the art. In: Economic Evaluation of Epilepsy Management. (Eds C. Pachlatko and R. G. Beran). London, John Libbey & Co., 1996: pp. 11-18.
10. Shakespeare, A. and Simeon, G. Economic analysis of epilepsy treatment: A cost minimization analysis comparing carbamazepine and lamotrigine in the U.K. Seizure 1998; 7: 119-125.
11. Landefeld, J. S. and Seskin, E. P. The economic value of life: Linking theory to practice. American Journal of Public Health 1982; 72: 555-566.
12. Thompson, M. S. Willingness to pay and accept risks to cure chronic disease. American Journal of Public Health 1986; 76: 392-396.
13. Johannesson, M. and Jönsson, B. Economic evaluation in health care: Is there a role for cost-benefit analysis? Health Policy 1991; 17: 1-23.
14. Gafni, A. Willingness-to-pay as a measure ofbenefits. Relevant questions in the context of public decision making about health care programs. Medical Care 1991; 29: 1246-1252.
15. Morrison, G. C. and Gyldmark, M. Appraising the use of contingent valuation. Health Economics 1992; 1: 233-243.
16. O'Brien, B. and Viramontes, J. L. Willingness to pay: A valid and reliable measure of health state preference? Medical Decision Making 1994; 14: 289-297.
17. Kartman, B., Andersson, F. and Johannesson, M. Willingness to pay for reductions in angina pectoris attacks. Medical Decision Making 1996; 16: 248-253.
18. Chestnut, L. G., Keller, L. R., Lambert, W. E. and Rowe, R. D. Measuring heart patients' willingness to pay for changes in angina symptoms. Medical Decision Making 1996; 16: 65-77.
19. Ryan, M. Valuing the Benefits of Health Care: Conjoint Analysis or Contingent Valuation? HERU Discussion Paper 2/93. Aberdeen, University of Aberdeen, Departments of Public Health and Economics, Health Economics Research Unit, 1993.
20. Jones-Lee, M. W. The Economics of Safety and Physical Risk. Oxford, Basil Blackwell, 1989.
21. Donaldson, C. Theory and Practice of Willingness to Pay for Health Care. HERU Discussion paper 1/93. Aberdeen, University of Aberdeen, Departments of Public Health and Economics, Health Economics Research Unit, 1993.
22. Johansson, P. O. Evaluating Health Risks. Cambridge, Cambridge University Press, 1995.
23. Anonymous. Glossary of terms used in health economics, and pharmacoeconomic and quality-of-life analyses. PharmacoEconomics 1997; 12: 612-615.
24. rd Edition. New York, John Wiley, 1953.
25. Torrance, G. W, Thomas, W. H. and Sackett, D. L. A utility maximization model for evaluation of health care programs. Health Services Research 1972; 7: 118-133.
26. Froberg, D. G. and Kane, R. L. Methodology for measuring health-state preferences I: Measurement strategies. Journal of Clinical Epidemiology 1989; 42: 345-354.
27. Nord, E. Methods for quality adjustment of life years. Social Science and Medicine 1992; 34: 559-569.
28. Revicki, D. A. and Kaplan, R. M. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Quality of Life Research 1993; 2: 477-487.
29. Stavem, K. Quality of life in epilepsy: Comparison of four preference measures. Epilepsy Research 1998; 29: 201-209.
30. Sintonen, H. A fifteen-dimensional measure of health-related quality of life (15D) and its applications. In: Quality of Life Assessment. Key Issues in the 1990s. (Eds S. R. Walker and R. Rosser). Dordrecht, Kluwer, 1993: pp. 185-195.
31. Sintonen, H. The 15D-measure of Health-related Quality of Life. I. Reliability, Validity and Sensitivity of its Health State Descriptive System. Working paper 41. Melbourne, Australia, National Centre for Health Program Evaluation, 1994.
32. Sintonen, H. The 15D-measure of Health-related Quality of Life. II. Feasibility, Reliability and Validity of its Valuation System. Working paper 42. Melbourne, Australia, National Centre for Health Program Evaluation, 1994.
33. EuroQol Group. Euroqol: A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
34. Donaldson, C., Shackley, P., Abdalla, M. and Miedzybrodzka, Z. Willingness to Pay for Antenatal Carrier Screening for Cystic Fibrosis. HERU Discussion Paper 4/93. Aberdeen, University of Aberdeen, Departments of Public Health and Economics, Health Economics Research Unit, 1993.
35. Richardson, J. and Nord, E. The importance of perspective in the measurement of quality-adjusted life years. Medical Decision Making 1997; 17: 33-41.
36. Gudex, C., Ed. Time Trade-off User Manual: Props and Selfcompletion Methods. York, University of York, Centre for Health Economics, 1994.
37. Olsen, J. A. and Donaldson, C. Willingness to Pay for Public Sector Health Programmes in Northern Norway. HERU Discussion Paper 5/93. Aberdeen, University of Aberdeen, Departments of Public Health and Economics, Health Economics Research Unit, 1993.
38. Krabbe, P. F., Essink-Bot, M. L. and Bonsel, G. J. The comparability and reliability of five health-state valuation methods. Social Science and Medicine 1997; 45: 1641-1652.